Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

• Published in: The Journal of heart and lung transplantation Vol. 38; no. 1; pp. 43 - 50
• Main Authors: Frost, Adaani, Janmohamed, Munir, Fritz, Jason S., McConnell, John W., Poch, David, Fortin, Terry Ann, Miller, Chad E., Chin, Kelly M., Fisher, Micah, Eggert, Michael, McEvoy, Colleen, Benza, Raymond L., Farber, Harrison W., Kim, Nick H., Pfister, Thomas, Shiraga, Yoko, McLaughlin, Vallerie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2019
• Subjects: Acetamides - administration & dosage; Administration, Inhalation; Administration, Oral; Antihypertensive Agents - administration & dosage; Dose-Response Relationship, Drug; Drug Substitution; Drug Tolerance; Epoprostenol - administration & dosage; Epoprostenol - analogs & derivatives; Female; Follow-Up Studies; Humans; inhaled treprostinil; Male; Middle Aged; Prodrugs; Prospective Studies; prostacyclin-pathway targeting therapy; pulmonary arterial hypertension; Pulmonary Arterial Hypertension - drug therapy; Pulmonary Arterial Hypertension - physiopathology; Pulmonary Wedge Pressure - physiology; Pyrazines - administration & dosage; selexipag; Treatment Outcome; treatment transition; selexipag; inhaled treprostinil; prostacyclin-pathway targeting therapy; pulmonary arterial hypertension; treatment transition

A long-term trial showed that the oral prostacyclin (PGl2) receptor (IP) agonist, selexipag, delayed disease progression in patients with pulmonary arterial hypertension (PAH). Transition to selexipag in patients treated with more burdensome inhaled therapies that target the prostacyclin pathway may...